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Background: Lymphoepithelioma-like carcinoma is an undifferentiated carcinoma with histological features similar
to undifferentiated, non-keratinizing carcinoma of the nasopharynx. Lymphoepithelioma-like carcinoma of the
urinary bladder is uncommon with a reported incidence of 0.3%– 1.3% of all bladder cancer. We report a Japanese
case of predominant lymphoepithelioma-like carcinoma of the urinary bladder and review all of the English
literature after performing a pooled analysis of the cases including the present one.
Case presentation: An 83-year-old Japanese man was introduced to our department with the chief complaint of
macroscopic hematuria. Cystoscopy demonstrated a thumb tip-sized bladder tumor at the trigone. The patient
underwent a transurethral resection of the bladder tumor. The pathological examination showed predominant
lymphoepithelioma-like carcinoma of the urinary bladder with urothelial carcinoma. The patient was diagnosed
with muscle invasive lymphoepithelioma-like carcinoma of the urinary bladder and was treated with concurrent
chemoradiotherapy. The patient is under observation with regular clinical follow-up and remains well after
12 months, with no evidence of disease recurrence. The reports of 93 patients including the present one of
lymphoepithelioma-like carcinoma of the urinary bladder from the English literature were collected between 1991
and 2014. Patients were evaluated for clinicopathological findings. Outcome resulted as follows: 59 patients (67%)
did not show evidence of disease, 14 (17%) died of disease, 5 (6%) was alive with metastases, and 9 (10%) died for
causes unrelated to the primary disease. Cause-specific survival rate resulted 83%. The overall patients were divided
into three groups (pure, predominant and focal) according to the lymphoepithelioma-like carcinoma of the urinary
bladder classification of Amin et al.
Conclusions: Because lymphoepithelioma-like carcinoma of the urinary bladder is more sensitive to both chemotherapy
and radiotherapy than conventional urothelial carcinoma, radical cystectomy may not be necessary for all patients with
muscle invasive lymphoepithelioma-like carcinoma of the urinary bladder. Therefore, pathological information may be
useful in selecting patients suitable for bladder-preservation treatment. On the other hand, the apparently more
aggressive nature of focal lymphoepithelioma-like carcinoma of the urinary bladder suggests that these patients are
probably best managed with radical cystectomy and adjuvant treatment.
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Undifferentiated, non-keratinizing carcinoma with pro-
minent lymphocytic infiltrate arising outside of the
nasopharynx is called lymphoepithelioma-like carcinoma
(LELC). Although LELC occurs in organs, such as saliv-
ary glands, uterine cervix, thymus, lung, skin, stomach,
and breast, its occurrence in the urinary system is very* Correspondence: uroltateki@yahoo.co.jp
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unless otherwise stated.rare. LELC of the urinary bladder (LELCB) has a re-
ported incidence of 0.3%– 1.3% of all bladder cancer
[1-3]. Contrary to nasopharynx cases, no relationship
with Epstein-Barr virus has been reported. According to
the lymphoepithelioma component, these tumors were
classified as pure (100%), predominant (≥50%), and focal
(<50%), advocated by Amin et al. [4].
Because of the small number of cases reported in the
literature, there are no clear guidelines for the treatment
of LELCB. Several reports suggest that, unlike conven-
tional urothelial carcinoma and focal LELCB, the purel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 2 Contrast-enhanced magnetic resonance imaging
(sagittal image) showed a bladder tumor (arrow) at the trigone,
20 × 17 × 15 mm in size, with muscle invasion.
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tive to chemotherapy and radiotherapy. This observation
raises the potential of salvaging bladder function in pa-
tients with these subtypes [1,2,4]. This advantage is lost
when the urothelial elements predominate.
Case presentation
An 83-year-old Japanese man was introduced to our
department with the chief complaint of macroscopic
hematuria. There was a past medical history of hepatitis
B and hepatocellular carcinoma treated with radiofre-
quency ablation, but no history of urological problems.
Physical examination and vital signs were unremarkable.
Urinalysis showed combined hematuria and pyuria, but
urine culture was sterile. Urine cytology indicated atypical
cells. Abnormal hematological findings include leukocytosis
(WBC count: 15,700/μl) and eosinophilia (12%). The serum
IgE level was 9.8 IU/ml (normal <173 IU/ml).
Cystoscopy demonstrated a thumb tip-sized bladder
tumor at the trigone (Figure 1) and papillary mucosa at
the left lateral wall. Contrast-enhanced magnetic reson-
ance imaging (MRI) showed a 20 × 17 × 15 mm bladder
tumor at the trigone and muscle invasion in the bladder
(Figure 2). Computed tomography (CT) revealed no dis-
tant metastases. The patient underwent transurethral re-
section of the bladder tumor (TURBT). Histopathological
examination revealed that 90% of the volume of the tumor
was LELC marked by syncytial growth pattern (Figure 3),
heavy lymphocytic infiltrate, necrosis, brisk mitosis and
muscle invasion. The epithelial cells expressed CK7 and
CK34βE12, and the lymphocytes CD3 and CD20 (Figure 4).Figure 1 Cystoscopy revealed a thumb tip-sized bladder tumor
at the trigone. The tumor was solid and broad-based. asterisk, flexible
cystoscope; arrow, neck of bladderThe rest of the tumor was composed of non-invasive
urothelial carcinoma.
The patient received concurrent chemoradiotherapy.
The chemotherapy regimen included gemcitabine ad-
ministered at 1000 mg/m2 on Days 1 and 8 and cisplatin
70 mg/m2 on Day 1 of a 21-day cycle. Radiotherapy,
60 Gy in total, was started on Day 1, concurrently with
chemotherapy.
Ten months after his initial visit to our department,
the patient underwent second TURBT for evaluation of
pathological effect. No viable cancer cells were detected
in the bladder specimens, including the muscle layer. At
the time of this writing, the patient is under observation
with regular clinical follow-up and remains well after
12 months, with no evidence of disease recurrence.
Materials and methods
On the basis of the review from 1991 to 2002 by Porcaro
AB et al. [5], we added subsequent LELCB reports to
the review and summarized. Conduct of this study con-
formed to the Declaration of Helsinki, and was approved
by our institutional ethical committee (Institutional Re-
view Board of Onomichi General hospital). The reports
of 93 patients including the present one of LELCB from
the English literature were collected from 1991 to 2014,
as shown in Table 1 [1-23]. Patients were evaluated for
age, sex, primary and adjuvant treatments, pathological
stage, follow-up and outcome, and cause-specific sur-
vival. Patients underwent cystoscopy and transurethral
resection of the tumor for both biopsy or complete re-
moval of the mass. Tumor specimens were evaluated for
local pathological stage (available in 92 cases), histo-
logical subtype according to the classification of Amin
et al. for LELCB. LELCB was classified as pure when
100% of the tumor showed lymphoepithelioma-like
Figure 3 Microscopic findings (left, ×100; right, ×400). Lymphoepithelioma-like carcinoma, syncytial pattern with prominent lymphocytic
infiltrate and lymphoepithelioma-like carcinoma with urothelial carcinoma.
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ciated with usual urothelial carcinoma, adenocarcinoma,
or squamous cell carcinoma. Mixed subtype in Table 2
was used synonymously with predominant or focal [6].
Primary treatments performed included TURBT, partial
cystectomy, and radical cystectomy. Adjuvant treatments,
when performed, included several courses of systemic
multiagent chemotherapy with MVAC (methotrexate,
vinblastine, doxorubicin, and cisplatin) or GC (gemcita-
bine, cisplatin), as well as intravesical chemotherapy
with doxorubicin or bacillus Calmette-Guerin, and
radiotherapy.
The overall patient population was separated into 3
groups according to the LELCB classification of Amin et al.
Each group was evaluated for the same clinical, patho-
logical features as described previously for the overall
population group.Figure 4 Immunohistochemical findings of CK7, CK34βE12, CD3, and
staining for CK34βE12 was detected. Positive staining with antibodies again
B-lymphocytes, respectively.Results
As shown in Table 1, 93 patients with LELCB were re-
ported from 1991 to 2014. Table 2 shows the features of
the overall patient population which included 48 males
and 17 females. Mean age was 70.0 years (range: 52–90).
Gross hematuria (GH) was seen in all available patients
with presenting symptoms. LELCB histological subtypes
resulted pure in 39 cases (43%), predominant in 26
(29%), focal in 13 (15%), and mixed in 12 (13%). Patients
with pT2 and pT3 together accounted for 83% of the pa-
tient population. Primary treatments included TURBT in
51 patients (55%), partial cystectomy in 6 (7%), and radical
cystectomy in 35 (38%). Adjuvant treatment, which was
not performed in 48 cases (52%), included systemic
chemotherapy in 21 (23%), radiotherapy in 14 (15%), che-
moradiotherapy in 6 (7%), and intravesical chemotherapy
in 3 (3%). Outcome resulted as follows: 59 patients (67%)CD20. The epithelial component revealed overexpression of CK7. Focal
st CD3 and CD20 showed abundant T-lymphocytes and less
Table 1 Reports of lymphoepithelioma-like carcinoma of the urinay bladder from the English literature including the
present case
Case no. Reference Year Sex Age Chief complaint Type Stage Treatment Follow-up Outcome
1 Zukerberg 1991 M 76 NA PU NA TURBT, RT NA NA
2 Young 1993 M 81 NA PU T3 PC, CH 41 DOD
3 Dinney 1993 M 52 GH PU T2 TURBT, CH 72 NED
4 Dinney 1993 M 68 GH PU T2 TURBT, CH 60 NED
5 Dinney 1993 M 63 NA PU T2 TURBT, CH 11 NED
6 Amin 1994 M 52 GH PU T2 TURBT, CH 72 NED
7 Amin 1994 M 68 GH PU T2 TURBT, CH 60 NED
8 Amin 1994 M 63 GH PU T2 TURBT, CH 11 NED
9 Amin 1994 F 71 GH PR T2 TURBT, CH 9 NED
10 Amin 1994 F 67 GH PR T3 PC, RT 36 NED
11 Amin 1994 M 55 GH PR T2 RC 10 NED
12 Amin 1994 M 71 GH PR T2 RC 6 NED
13 Amin 1994 F 79 GH PR T3 RC 2 NED
14 Amin 1994 M 78 GH F T2 RC, CH 84 DOD
15 Amin 1994 M 66 GH F T3 RC 6 DOD
16 Amin 1994 M 68 GH F T1 RC 0 DWD
17 Bianchini 1996 M 72 NA PU T3 RC, CH 29 NED
18 Holmäng 1998 F 61 GH PU T2 TURBT, RT 216 DWD
19 Holmäng 1998 M 78 GH PU T1 TURBT, RT 13 DWD
20 Holmäng 1998 M 65 GH PU T2 TURBT 24 NED
21 Holmäng 1998 F 71 GH PR T3 TURBT, RT 21 DWD
22 Holmäng 1998 F 60 GH PR T3 RC, RT 104 NED
23 Holmäng 1998 F 65 GH PR T3 PC 76 NED
24 Holmäng 1998 F 84 GH F T1 TURBT 66 DOD
25 Holmäng 1998 M 72 GH F T3 RC, RT 68 DOD
26 Holmäng 1998 M 71 GH F T3 TURBT, RT 9 DOD
27 Constantinides 2001 M NA GH, Urgency PU T2 TURBT, CH 34 NED
28 Constantinides 2001 M NA GH, Urgency PU T1 TURBT, IV-CH 28 NED
29 Constantinides 2001 M NA GH, Urgency PR T2 RC 32 NED
30 Lopez-B 2001 F 69 NA PU T2 TURBT, CH 21 NED
31 Lopez-B 2001 M 72 NA PU T3 RC 32 NED
32 Lopez-B 2001 M 81 NA PU T2 TURBT, CH 47 NED
33 Lopez-B 2001 M 69 NA PR T2 TURBT 22 NED
34 Lopez-B 2001 F 67 NA PR T2 RC 22 NED
35 Lopez-B 2001 M 73 NA PR T3 RC 37 NED
36 Lopez-B 2001 M 82 NA PR T2 TURBT 49 NED
37 Lopez-B 2001 M 74 NA PR T2 TURBT 25 AWM
38 Lopez-B 2001 F 81 NA PR T2 TURBT 44 DOD
39 Lopez-B 2001 M 78 NA F T2 TURBT 3 DOD
40 Lopez-B 2001 F 58 NA F T2 RC 19 DOD
41 Lopez-B 2001 M 71 NA F T2 TURBT 30 DOD
42 Lopez-B 2001 M 69 NA F T3 RC 18 DOD
43 Ward 2002 M 61 GH PR T2 TURBT NA NA
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Table 1 Reports of lymphoepithelioma-like carcinoma of the urinay bladder from the English literature including the
present case (Continued)
44 Porcaro 2003 M 72 NA PR T2 TURBT 17 NED
45 Chen 2003 M 73 GH PU T3 RC, CH 26 NED
46 Chen 2003 M 63 GH PU T1 TURBT, IV-CH 26 NED
47 Izuquierdo 2004 M 77 GH PU T2 TURBT, RT 39 NED
48 Izuquierdo 2004 F 82 GH PR T2 TURBT 36 NED
49 Izuquierdo 2004 M 74 GH F T2 TURBT, RT 54 NED
50 Guresci 2005 M 90 GH PR T3 TURBT NA NA
51 Abascal 2005 M 54 GH NA T3 NA NA NA
52 Yaqoob 2005 F 55 GH, Miction pain NA T2 TURBT NA NA
53 Mayer 2007 M 57 GH PU T1 RC 36 NED
54 Tamas 2007 NA NA NA PU T3 PC 23 AWM
55 Tamas 2007 NA NA NA PU T2 RC 40 NED
56 Tamas 2007 NA NA NA PU T4 RC, RT 36 NED
57 Tamas 2007 NA NA NA PU T3 RC 42 NED
58 Tamas 2007 NA NA NA PU T2 RC 46 NED
59 Tamas 2007 NA NA NA PU T4 RC, CH 29 NED
60 Tamas 2007 NA NA NA PU T3 RC 23 NED
61 Tamas 2007 NA NA NA PU T2 RC 3 DWD
62 Tamas 2007 NA NA NA PU T2 TURBT, CH, RT 17 NED
63 Tamas 2007 NA NA NA PU T2 TURBT, Thermal, CH 4 NED
64 Tamas 2007 NA NA NA PU T1 TURBT, RT 6 NED
65 Tamas 2007 NA NA NA PU T3 RC 4 NED
66 Tamas 2007 NA NA NA PU T2 TURBT, RT, CH 65 DWD
67 Tamas 2007 NA NA NA PU T1 TURBT, IV-CH 38 NED
68 Tamas 2007 NA NA NA PU T1 TURBT 48 DWD
69 Tamas 2007 NA NA NA PU T2 RC 2 NED
70 Tamas 2007 NA NA NA Mixed T3 RC 55 NED
71 Tamas 2007 NA NA NA Mixed T2 TURBT, RT, CH 24 NED
72 Tamas 2007 NA NA NA Mixed T2 PC 10 NED
73 Tamas 2007 NA NA NA Mixed T2 TURBT 4 AWM
74 Tamas 2007 NA NA NA Mixed T1 TURBT, CH 6 NED
75 Tamas 2007 NA NA NA Mixed T1 TURBT 42 DWD
76 Tamas 2007 NA NA NA Mixed T1 RC 9 NED
77 Tamas 2007 NA NA NA Mixed T2 TURBT, CH 2 NED
78 Tamas 2007 NA NA NA Mixed T2 TURBT, RT, CH 8 AWM
79 Tamas 2007 NA NA NA Mixed T1 RC 18 DOD
80 Tamas 2007 NA NA NA Mixed T3 RC 5 AWM
81 Tamas 2007 NA NA NA Mixed T2 PC 2 NED
82 Singh 2009 M 69 GH PU T2 RC 12 NED
83 Trabelsi 2009 M 58 GH NA T2 RC NA NA
84 Yun 2010 F 78 GH PR T1 TURBT 8 NED
85 Kozyrakis 2011 M 72 GH PR T2 TURBT, RT 72 NED
86 Kozyrakis 2011 M 75 GH PR T3 RC, CH 26 NED
87 Kozyrakis 2011 F 80 GH PR T2 TURBT, RT 13 NED
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Table 1 Reports of lymphoepithelioma-like carcinoma of the urinay bladder from the English literature including the
present case (Continued)
88 Kozyrakis 2011 F 69 GH PR T3 RC, CH 34 DWD
89 Kozyrakis 2011 M 70 GH F T2 TURBT 14 DOD
90 Kozyrakis 2011 M 72 GH F T2 TURBT, RT, CH 27 DOD
91 Pantelides 2012 M 64 GH PU T2 TURBT, CH 6 NED
92 Mori 2013 M 70 GH PR T2 RC 10 NED
93 Present case 2014 M 83 GH PR T2 TURBT, CH, RT 12 NED
NA Not available, GH Gross hematuria, PU pure, PR Predominant, F Focal, TURBT Transurethral resection of the bladder tumor, PC Partial cystectomy, RC Radical
cystectomy, CH Chemotherapy, RT Radiotherapy, IV-CH Intravesical chemotherapy, NED Not evidence of disease, DOD Died of disease, DWD Died without disease,
AWM Alive with metastases.
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disease, 5 (6%) was alive with metastases, and 9 (10%)
died for causes unrelated to the primary disease. Cause-
specific survival rate resulted 83% in the overall patient
population.
Table 3 shows the results related to the three groups
of patients with LELCB according to their histological
classification: pure (group 1), predominant (group 2),
and focal (group 3). Mean age resulted about 70 years in
all groups. Pathological stage T2 and T3 together was
detected in 76–97% of patients in each group. More
than 90% of patients underwent TURBT or radical cyst-
ectomy as the primary treatment in all groups. Adjuvant
treatment was as follows: Systemic chemotherapy was
performed in 15 patients (38%) of the group 1, 3 (12%)
of the group 2, and 1 (8%) of the group 3. Radiation was
performed in 6 patients (16%) of the group 1, 5 (19%) of
the group 2, and 3 (23%) of the group 3. Chemoradiation
was done as adjuvant treatment in 2 patients (5%) of the
group 1, 1 (4%) of the group 2, and 1 (8%) of the group
3. Intravesical chemotherapy was performed in 3 pa-
tients (8%) of the group 1. Adjuvant treatment was not
performed in 13 patients (33%) of the group 1, 17 (65%)
of the group 2, and 8 (61%) of the group 3. Patients with
no evidence of disease were more than 80% of patients
in the group 1 and 2, whereas 8% in the group 3. Pa-
tients who died of their disease resulted 84% of patients
in the group 3, whereas less than 5% in the group 1 and
2. Though cause-specific survival rate resulted more
than 90% in the group 1 and 2 (mean follow-up 35.2 and
30.1 months, respectively), it was 15% in the group 3
(mean follow-up 30.6 months).
Discussion
LELCB affects primarily the elderly with male predomin-
ance, 74% of cases reported in the literature (Table 2).
With respect to chief complaint, GH was observed in all
available patients with presenting symptoms. Most pa-
tients with LELCB have muscle invasive T2–3 disease,
regardless of histological classification (pure, predominant,
and focal). In fact, as shown in Tables 2 and 3, LELCBpatients with T2–3 stage resulted 83% in overall popula-
tion, 76% in group 1 (pure), 97% in group 2 (predominant),
and 85% in group 3 (focal). Despite its infiltrative predis-
position, the metastatic potential of LELC seems to be low
[1,6]. LELCB is diagnosed at less advanced stages and has
a more favorable long-term prognosis than other types of
undifferentiated invasive carcinoma of the bladder.
The histological features of LELCB include an inflam-
matory infiltrate and a dense lymphocytic infiltrate; fur-
thermore, the syncytial arrangement of large neoplastic
epithelial cells with prominent nuclei and nucleoli can
be observed [24,25]. Once LELCB is identified, a primary
tumor in the nasopharynx should be excluded with CK7
stain. Nasopharyngeal carcinomas do not express CK7.
Other differential diagnosis usually includes malignant
lymphoma, undifferentiated urothelial carcinoma with
prominent lymphoid infiltrate, chronic cystitis, and small
cell carcinoma of the bladder [1,2,4,7]. These can be ex-
cluded by relevant immunohistochemistry [1,2,4,8,26].
In Table 2, a previous pooled analysis showed that at
a mean follow-up of 30.4 months, 67% of the overall
population did not show any evidence of disease with a
cause-specific survival rate of 83%. The cause-specific
survival rate was more than 90% for both pure and
predominant LELCB (mean follow-up of 35.2 and
30.1 months, respectively), whereas it was 15% (mean
follow-up 30.6 months) for focal LELCB. The pure and
predominant subtypes are more favorable than the focal
subtype in prognosis, which may be related to the in-
flammatory infiltrate that results in a strong immune
response against the atypical cells [4], early presentation
of lower urinary tract symptoms [2], and to the chemor-
adiosensitivity of the neoplastic cells. This prognosis
may be related to the host response, seen as a dense
infiltrate composed predominantly of T-lymphocytes in
the tumor [4], similar to medullary carcinoma of the
breast and seminoma which also contain T-lymphocytes.
To date, owing to the scarcity of reported cases, there
are no clear guidelines for the treatment of LELCB whose
biological behavior differs from that of conventional
urothelial carcinoma. Primary treatments for LELCB
Table 2 Lymphoepithelioma-like carcinoma of the urinary
bladder: clinical and pathological results in 93 cases
Features Patient population
Sex (n = 65)
Male 48 (74%)
Female 17 (26%)
Age (n = 62)
Mean 70.0
Range 52-90
Chief complaint (n = 35)
GH 31 (88%)
GH and Urgency 3 (9%)
GH and Miction pain 1 (3%)










Primary treatment (n = 92)
TURBT 51 (55%)
Partial cystectomy 6 (7%)
Radical cystectomy 35 (38%)
Adjuvant treatment (n = 92)
Systemic chemotherapy 21 (23%)
Radiotherapy 14 (15%)
Chemoradiotherapy 6 (7%)
Intravesical chemotherapy 3 (3%)
Not performed 48 (52%)
Follow-up (n = 87)
Mean 30.4 (months)
Range 0-216 (months)
Outcome (n = 87)
Not evidence of disease (NED) 59 (67%)
Died of disease (DOD) 14 (17%)
Died without disease (DWD) 9 (10%)
Alive with metastases (AWM) 5 (6%)
Cause-specific survival rate 83%
GH Gross hematuria, TURBT Transurethral resection of the bladder tumor.
Table 3 Lymphoepithelioma-like carcinoma of the urinary
bladder: histological subgroups according to the







Number of patients 39 (49%) 26 (34%) 13 (17%)
Male 21 14 11
Female 2 12 2
NA 16 - -
Age
Mean 67.8 72.7 71.6
Range 52-81 55-90 58-84
Stage
T1 7 (18%) 1 (3%) 2 (15%)
T2 21 (54%) 16 (62%) 7 (54%)
T3 8 (22%) 9 (35%) 4 (31%)
T4 2 (6%) - -
Primary treatment
TURBT 23 (59%) 14 (54%) 7 (54%)
Partial cystectomy 2 (5%) 2 (8%) -
Radical cystectomy 14 (36%) 10 (38%) 6 (46%)
Adjuvant treatment
Systemic chemotherapy 15 (38%) 3 (12%) 1 (8%)
Radiotherapy 6 (16%) 5 (19%) 3 (23%)
Chemoradiotherapy 2 (5%) 1 (4%) 1 (8%)
Intravesical chemotherapy 3 (8%) - -
Not performed 13 (33%) 17 (65%) 8 (61%)
Follow-up
Mean 35.2 30.1 30.6
Range 2-216 2-104 0-84
Outcome
Not evidence of disease (NED) 31 (81%) 20 (84%) 1 (8%)
Died of disease (DOD) 1 (3%) 1 (4%) 11 (84%)
Died without disease (DWD) 5 (13%) 2 (8%) 1 (8%)
Alive with metastases (AWM) 1 (3%) 1 (4%) -
Cause-specific survival rate 97% 95% 15%
GH Gross hematuria, TURBT Transurethral resection of the bladder tumor.
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LELCB is sensitive to both cisplatin-based chemother-
apy and radiotherapy, both of which have been used asadjuvant treatments after TURBT or radical bladder
surgery [1,2,4]. Adjuvant combination chemotherapy
includes three to five courses of methotrexate, vinblast-
ine, doxorubicin, and cisplatin [1,2,4,9,26]. As shown
in Table 3, the highest mortality was detected in the pa-
tients with focal LELCB who had local radical surgery,
which was not followed by any adjuvant treatment in
61% of the patients. At about the same mean follow-up
as focal subtype (group 3), 84% of the patients with pre-
dominant LELCB were alive and disease free although 65%
of patients did not undergo any adjuvant treatment. These
Yoshino et al. BMC Research Notes 2014, 7:779 Page 8 of 9
http://www.biomedcentral.com/1756-0500/7/779findings indicate that adjuvant treatment with chemo-
therapy and/or radiotherapy after local treatment of
the primary tumor is advised for patients presenting
with focal LELCB. Bladder-preservation therapy by per-
forming both TURBT alone or combined with adjuvant
chemotherapy and/or radiotherapy may be a reasonable
option for patients with pure or predominant LELCB,
whereas radical surgery with adjuvant treatment may be
indicated for focal LELCB with muscle invasion. In
addition, because the focal LELCB patients treated with
even radical surgery alone had comparatively short
survival (6, 18, and 19 months) in Table 1, we thought
that adjuvant treatment was essential for procedure of
focal LELCB. As shown in Tables 1 and 3, most patients
(84%) with focal LELCB died of the primary tumor,
whereas two patients of them, who underwent radical
cystectomy and adjuvant treatment, had a relatively
favorable outcome (64 and 84 months in survival). The
apparently more aggressive nature of focal LELCB
suggests that these patients are probably best managed
with radical cystectomy and adjuvant treatment.
The present case was predominantly composed of
LELCB accompanied by non-invasive urothelial carcin-
oma. On the basis of recommendations in the published
literature, the patient underwent concurrent chemoradio-
therapy after TURBT, leading to bladder-preservation.
Twelve months after the initial visit, no evidence of disease
recurrence was observed.
Previous reports and our experience suggest that rad-
ical cystectomy may not be necessary for all patients
with muscle invasive LELCB and that radiotherapy and
chemotherapy may be reliable treatment options. As
Kozyrakis et al. [3] also said, pathological information
might be useful in selecting patients suitable for
bladder-preservation treatment. However, a large-scale
study with long-term follow-up is needed to better
understand the biological behavior of LELCB.Conclusion
Because LELCB is sensitive to both chemotherapy and
radiotherapy, radical cystectomy may not be necessary
for all patients with muscle invasive LELCB. Therefore,
pathological information might be useful in selecting pa-
tients suitable for bladder-preservation treatment.
The apparently more aggressive nature of focal LELCB
suggests that these patients are probably best managed
with radical cystectomy and adjuvant treatment.Consent
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